Nephros (NEPH) Announces Earnings Results

Nephros (OTCMKTS:NEPH) issued its quarterly earnings results on Tuesday. The company reported ($0.01) earnings per share for the quarter, Morningstar.com reports. Nephros had a negative net margin of 25.82% and a negative return on equity of 82.57%. The business had revenue of $1.61 million during the quarter.

NEPH stock opened at $0.54 on Wednesday. The company has a quick ratio of 4.81, a current ratio of 5.81 and a debt-to-equity ratio of 0.13. Nephros has a one year low of $0.38 and a one year high of $0.73. The stock has a market cap of $35.94 million, a price-to-earnings ratio of -10.73 and a beta of 0.79.

Separately, Zacks Investment Research raised shares of Nephros from a “sell” rating to a “hold” rating in a research note on Tuesday, January 1st.

TRADEMARK VIOLATION WARNING: This news story was posted by Dakota Financial News and is the sole property of of Dakota Financial News. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://dakotafinancialnews.com/2019/03/13/nephros-neph-announces-earnings-results.html.



Nephros Company Profile

Nephros, Inc, a commercial stage medical device and commercial product company, develops and sells liquid purification filters and hemodiafiltration (HDF) systems primarily in the United States. The company's ultrafilters are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from water borne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities.

See Also: What are the benefits of a balanced fund?

Earnings History for Nephros (OTCMKTS:NEPH)

Receive News & Ratings for Nephros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nephros and related companies with MarketBeat.com's FREE daily email newsletter.